Connect with us

Press Releases

Volition Announces Launch of Nu.Q Vet Cancer Screening Test in U.S. & Europe Through Heska’s Reference Laboratories

The Nu.Q Vet Cancer Screening Test is a simple, easy-to-use blood test to detect common canine cancers early, even before symptoms appear.

mm

Published

on

(PRESS RELEASE) HENDERSON, NV — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announces the launch of its Nu.Q Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation (NASDAQ: HSKA) (“Heska”), a leading global provider of advanced veterinary diagnostics, through Heska’s veterinary diagnostic laboratories.

Steve Eyl, Heska’s chief commercial officer and president, scil animal company, said, “Our team has been working closely with Volition over the past six months and we are delighted to launch Volition’s Nu.Q Vet Cancer Screening Test in the U.S. and announce the forthcoming launch in Europe expected in the coming weeks through our veterinary diagnostics laboratories. The accurate, affordable, and non-invasive diagnostic for cancer screening and monitoring in canines is an ideal fit within Heska’s expanding portfolio of best-in-class solutions. This is an important achievement in our transformative work together as we move towards the launch of our flagship point of care solution anticipated in 2023.”

Dr. Tom Butera, chief executive officer of Volition Veterinary Diagnostics Development LLC, said, “We’re thrilled to be working alongside Heska and support the launch of the Nu.Q Vet Cancer Screening Test in the United States and Europe. It is another key milestone for us, as we press ahead with our aim to ensure as many veterinarians as possible can access our Nu.Q Vet Cancer Screening Test for the pets and pet owners who trust them.

“There are approximately 84 million pet dogs in the United States and approximately half of dogs will have at least one veterinary care visit each year. Implementing the Nu.Q Vet Cancer Screening Test at annual wellness visits can help detect cancer at an early stage, even before symptoms appear, allowing for a better chance of effective treatment and improved outcomes.”

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s Nu.Q technology go here.

About Heska

Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production under third-party agreements and channels, primarily for herd animal health. For more information, please visit www.heska.com.

Advertisement
About Volition

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

The contents found at Volition’s and Heska’s website addresses are not incorporated by reference into this document and should not be considered part of this document. Such website addresses are included in this document as an inactive textual references only.

Advertisement

FEATURED VIDEO

P.L.A.Y. Media Spotlight

At P.L.A.Y. — Pet Lifestyle & You — toy design is definitely a team effort! Watch PETS+ interviewer Chloe DiVita and P.L.A.Y.’s Director of Sales Lisa Hisamune as they talk about the toy design process, the fine-tuning that makes each toy so special and why every P.L.A.Y. collection is made with independent retailers top of mind.

Promoted Headlines

Advertisement

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news
and business ideas from PETS+.

Instagram

Most Popular